Drugs / KET-AD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07644767 | Oct 2026 → Jan 2028 expected | — | Neurocentrx Pharma Pty Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KET-AD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07644767 ↗ |
| Route | Oral | “administered orally 3 times a week” NCT07644767 ↗ |